Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05369013Unknown

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Role: collaborator

NCT03962608Not ApplicableWithdrawn

Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis

Role: collaborator

NCT04756310Not ApplicableCompleted

Study of Nutritional Supplementation in Patients With Unilateral Wet AMD

Role: collaborator

NCT03202498Not ApplicableTerminated

Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

Role: collaborator

NCT04271839Phase 4Withdrawn

Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

Role: collaborator

NCT03852914Not ApplicableUnknown

Efficacy and Safety of Intraarticular Sodium Hyaluronate Single Injection in Patients With Osteoarthritis of the Knee

Role: collaborator

All 6 trials loaded